Description:
ANTI-CDKL5 (350-650 HUMAN)
|
Repository
|
Orphan Disease Center
|
| Protocols |
2 Anti-CDKL5350650 Datasheet |
|
Species
|
Homo sapiens
|
|
Common Name
|
Human
|
|
Remarks
|
|
|
References
|
OR00047 has been referenced in the following publications:
Muñoz IM, Morgan ME, Peltier J, Weiland F, Gregorczyk M, Brown FC, Macartney T, Toth R, Trost M, Rouse J. Phosphoproteomic screening identifies physiological substrates of the CDKL5 kinase. EMBO J. 2018 Dec 14;37(24):e99559. doi: 10.15252/embj.201899559.
Kontaxi C, Ivanova D, Davenport EC, Kind PC, Cousin MA. Epilepsy-Related CDKL5 Deficiency Slows Synaptic Vesicle Endocytosis in Central Nerve Terminals. J Neurosci. 2023 Mar 15;43(11):2002-2020. doi: 10.1523/JNEUROSCI.1537-22.2023.
Castano A, Silvestre M, Wells CI, Sanderson JL, Ferrer CA, Ong HW, Lang Y, Richardson W, Silvaroli JA, Bashore FM, Smith JL, Genereux IM, Dempster K, Drewry DH, Pabla NS, Bullock AN, Benke TA, Ultanir SK, Axtman AD. Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology. Elife. 2023 Jul 25;12:e88206. doi: 10.7554/eLife.88206.
|
| Remarks |
Polyclonal anti-CDKL5 (350-650 human) antibody raised in sheep (S957D) and affinity purified against amino acids 350–650 of human CDKL5 expressed in bacteria (plasmid DU50406). Aliquots are provided at 0.1mg in PBS. Working concentration for immunoblotting use 0.5 - 1 ug/ml. Working concentration for immunoprecipitation use 1 ug antibody per 1 mg of cell extract. |
|